Forest Laboratories (FRX) - FREE Research Report

Solomon Howard who is Director at Forest Laboratories sold 250,000 shares at $65.41 on Jan. 27, 2014. Following this transaction, the Director owned 464,881 shares meaning that the stake was reduced by 34.97% with the 250,000-share transaction.

The shares most recently traded at $65.19, down $0.22, or 0.33% since the insider transaction. Historical insider transactions for Forest Laboratories go as follows:

  • 4-Week # shares sold: 250,000
  • 12-Week # shares sold: 250,000
  • 24-Week # shares sold: 263,104

The average volume for Forest Laboratories has been 2.1 million shares per day over the past 30 days. Forest Laboratories has a market cap of $17.5 billion and is part of the health care sector and drugs industry. Shares are up 8.51% year-to-date as of the close of trading on Monday.

Forest Laboratories, Inc. develops, manufactures, and sells branded forms of ethical drug products in the United States and Europe. The company has a P/E ratio of 114.0. Currently there are 11 analysts that rate Forest Laboratories a buy, no analysts rate it a sell, and 9 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on FRX - FREE

TheStreet Quant Ratings rates Forest Laboratories as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, compelling growth in net income, solid stock price performance, impressive record of earnings per share growth and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Forest Laboratories Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

National Instruments Has More Room on the Upside

21 Buzzwords That Goldman Sachs Thinks All Investors Should Know Now

Insiders Are Scooping Up These 5 Stocks Right Now

Insider Trading Alert - NATI, PCLN And LQ Traded By Insiders

Trifecta Stocks: Concerns Rise Amid Weak GDP Forecast, So-So Store Sales

Trifecta Stocks: Concerns Rise Amid Weak GDP Forecast, So-So Store Sales